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Drug-resistant microorganisms pose an enormous threat to public health. Here we provide examples of
experimental approaches that offer novel ways to think about drug development considering the complexity
inherent to host-pathogen interactions. Emergent themes include (1) targeting pathogenicity rather than
microbial growth, (2) targeting the host or host-pathogen interface rather than the pathogen, (3) facilitating
pathogen-specific immune responses, and (4) utilizing systems-based approaches to identify new drug
targets and validate drug efficacy. We posit that together these approaches may allow identification of drugs
that disrupt pathogenesis and allow the immune system time to protect, but do not easily engender resis-





Various bacterial species use intercellular
communication, including quorum
sensing, to regulate a wide variety of
processes. Intercellular communication is
mediated by synthesis, secretion, and
detection of pheromone-like molecules
called autoinducers, which accumulate
extracellularly when bacteria achieve
a sufficient population density. Autoin-
ducers include acyl-homoserine lactones
(Nealson et al., 1970;Reading and Speran-
dio, 2006), steroids (e.g., cholesterol deriv-
atives [Williams et al., 2004]), aromatic
molecules (e.g., AI-3 [Sperandio et al.,
2003]), and other small molecules (e.g.,
phenazines [e.g., Mahajan-Miklos et al.,
1999]). These molecules regulate their
own production as well as the transcription
of other genes such as virulence factors.
Autoinducers can have a myriad of effects
not only on the bacteria but also on
the host (reviewed in Reading and Speran-
dio, 2006). Recent evidence suggests that
intercellular communication between pa-
thogens and commensals—and between
pathogens and the host—can at least in
part contribute to activation of virulence
mechanisms (Kaper and Sperandio,
2005; Kendall and Sperandio, 2007).
An example of how quorum-sensing
systems are used during pathogenesis islosis (MTB) XDR is particularly worrisome,
because it is highly fit and causes rapid
death in HIV+ patients (16 days on
average post diagnosis [Koenig, 2008]).
MTB represents only the tip of the drug-
resistance iceberg; a plethora of microbes
exist today for which few if any effective
drugs are available.
In this Perspective, we discuss several
novel ways to approach drug design
based on a detailed understanding of the
complexity inherent to host-pathogen
interactions, and in particular on those
aspects that can be manipulated to
disrupt disease without easily engen-
dering resistance. Our goal here is not to
provide a comprehensive review of host-
pathogen systems nor of translational
strategies. Rather, we highlight recent
advances in each of several areas,
including quorum sensing, host targets,
and immunomodulators, which have in
our view shown promise and may have
applicability to a wide variety of patho-
gens. Finally, we consider tools developed
in other areas of biological endeavor (e.g.,
cancer and systems biology) that may be
applicable to understanding complexities
of host-pathogen systems—and which
may facilitate both new biological under-
standing and the design of new drugs.
We have highlighted the strengths of these
approaches, as well as the potential
hurdles still to be overcome. Nevertheless,
space limitations precluded a comprehen-
sive review, and we have not considered
vaccines nor immunomodulators or thera-Microbial pathogens have proven to be
a formidable opponent for most of human
history. Although antibiotics and other
antimicrobial compounds have been
enormously successful in curbing the
death toll, the rise of drug-resistant
microbes has threatened to nullify those
gains. Alexander Flemming recognized
this problem in 1945, noting in his Nobel
lecture:
‘‘The time may come when peni-
cillin can be bought by anyone in
the shops. Then there is the danger
that the ignorant man may easily
underdose himself and by exposing
his microbes to nonlethal quantities
of the drug make them resistant.’’
It has been well established that resis-
tance in both bacteria and viruses can
be countered by administration of
multiple drugs affecting multiple systems
within the microbe. However, microbes
are capable of surviving strong selective
pressure even from multiple antimicrobial
compounds. The problem is exacerbated
by indiscriminate administration of drugs,
which mitigates the selective pressure
and facilitates development of resistant
strains. With pathogens that cause
chronic disease and require long-term
administration of drugs, compliance has
become the single most important factor
in engendering the development of
multiple or extensively drug resistant
(XDR) strains. Mycobacterium tubercu-
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PerspectiveFigure 1. Targeting Two-Component Regulatory Systems to Reduce Virulence in Pathogenic E. coli
(A) EPEC causes formation of actin-filled membranous protrusions, called pedestals, beneath itself upon attachment to intestinal epithelia. Actin is pseudocol-
ored green, and the bacteria blue.
(B) Virulence factors within the LEE pathogenicity island orchestrate pedestal formation. These factors are under the control of the QseBC two-component regu-
latory system, which is itself regulated by quorum-sensing signals such as AI-3 and host-derived signals such as epinephrine (epi) and norepinephrine (NE), and
inhibited by small molecules (LED209). Provided by V. Sperandio after Rasko et al. (2008).
(C) Cocrystal structures of a two-component regulatory system composed of a response regulator (RR) and a histidine kinase(HK) illustrate interaction surfaces
that may be targeted to disrupt virulence. Provided by M. Laub after Paul et al. (2008).Cell Host & Microbe 5may not necessarily work once infection
has been established. This is likely the
case with Franciscella infections, which,
once established, cripple the immune
system. Moreover, it isn’t clear that drugs
targeting pathogenic mechanisms will
engender resistance less readily than
cidal antimicrobials, because loss of
advantages afforded by quorum-sensing
systems may render the pathogen less
competitive with respect to commensal
strains. However, such drugs may be
effective in the concert with other drugs
that disrupt the activity of virulence
factors per se or with traditional antimi-
crobials. In this regard, even modest
reductions in load can be extremely
beneficial. For example, the mutation
frequency of MTB for kanamycin is 107;
thus, reductions in load by 10- to 100-
fold using a coadministered drug signifi-
cantly reduce the probability of devel-
oping resistance to kanamycin, and
thereby extend the life span of both drugs.
Targeting QseC represents a strategy
for drug design that relies on selecting
for targets that regulate virulence rather
than growth. Two-component regulatory
systems are remarkably widespread in
bacteria and are used to maintain the
specificity of signaling systems. Recent
work from a variety of groups has focused
on how, given the remarkable conserva-
tion of such molecules, cells maintain
the insulation of some pathways and mini-
mize crosstalk, yet allowing integration
of others. Laub and colleagues have
found that specificity in two-component
signaling systems is intrinsic to the mole-
cules, and have mapped domains and
amino acids that dictate sensor kinaseaddition, the QseBC system regulates
indirectly expression of operons within
the LEE (Reading et al., 2007) and other
factors required for virulence and survival
(e.g., Burton et al., 2002). Interestingly,
norepinephrine and adrenaline derived
from the host can substitute for AI-3 and
activate QseC (Waldor and Sperandio,
2007). Thus, both interkingdom signals
and intercellular signals from other EHEC
or from commensals can regulate the
virulence program (Hughes and Speran-
dio, 2008). In this case, such plasticity
may serve as a means by which the path-
ogen can activate its virulence program
both early in infection, when multitude of
commensal strains are present, and later
as the bacteria disseminates outside the
colon to areas where few other bacteria
are present.
Therapeutic Options that Target
Two-Component Regulatory
Systems
Can two-component regulatory systems
be targeted therapeutically? Recent
evidence suggests that small molecules
targeting the QseC system effectively
eliminate transcription of LEE genes
and disrupt pathogenesis of EHEC
(Figure 1B) (Rasko et al., 2008). Notably,
QseC homologs are present in several
other bacterial pathogens—including
various Salmonella species, Vibrio para-
haemolyticus, and Francisella tularensis
(e.g., Merighi et al., 2006)—and regulate
virulence. Remarkably, the small mole-
cule targeting EHEC QseC is also active
against Francisella tularensis in vitro and
in vivo. Importantly, small molecules that
target activation of virulence programsthe regulation of QseC by intercellular
signaling factors in enteropathogenic
Escherichia coli (EPEC) and enterohemor-
rhagic E. coli (EHEC) O157:H7. EPEC and
EHEC are food-borne pathogens. EPEC
causes diarrhea and high infant morbidity
in developing countries (Frankel et al.,
1998), whereas EHEC expresses Shiga-
like toxins not present in EPEC and
causes major outbreaks of bloody diar-
rhea and hemolytic uremic syndrome
throughout the world (Karch et al., 2005).
Both EPEC and EHEC colonize the intes-
tinal tract and cause attaching and
effacing (A/E) lesions on epithelial cells.
A/E lesions are characterized by the
destruction of microvilli and formation
of actin-filled membranous protrusions
beneath attached bacteria (Moon et al.,
1983) (Figure 1A). The genes that direct
the formation of A/E lesions are clustered
in a chromosomal pathogenicity island
called the locus of enterocyte effacement
(LEE) and encode transcriptional regula-
tors, a type III secretion (T3S) system,
and various virulence factors (Frankel
et al., 1998; McDaniel et al., 1995).
Several reports suggest that quorum
sensing may be important not only for
communication between EHEC cells, but
also between EHEC and commensal
E. coli resident in the intestine, and may
be a signal by which EHEC ramps up viru-
lence factor production once it reaches
the appropriate part of the intestine.
Upon sensing the autoinducer AI-3, the
two-component sensor kinase QseC
phosphorylates the response regulator
QseB, which activates the expression of
motility genes and itself (Reading et al.,
2007; Waldor and Sperandio, 2007). In, February 19, 2009 ª2009 Elsevier Inc. 115
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Life cycle of poxvirus illustrates redundant usage of tyrosine kinases of the Abl and Src families for actin tail
formation and release, and the utility of dual Src-Abl inhibitors (e.g. PD-166326) or Abl family specific inhib-
itors (Gleevec) in preventing spread. The virus replicates in extranuclear factories, and transits through
a golgi-like compartment, where it becomes wrapped in host-derived membranes. After transit to the
cell surface along microtubules, the virus fuses with the plasma membrane, where it initiates formation
of actin-filled membranous protrusions, called tails, beneath itself, which propels the virion towards,
and even into, apposing cells. The virus then detaches. Tail formation and release from the cell surface
both depend on tyrosine kinases. Inset: Image of actin tail. Actin is pseudocolored green, and the Abl tyro-
sine kinase red. Adapted from Reeves et al. (2005) and used with permission of Nature Medicine.116 Cell Host & Microbe 5, February 19, 200or by utilizing classes of host molecules
in a redundant fashion, thereby broad-
ening their host range. Poxviruses illus-
trate how a pathogen can usurp host
tyrosine kinases to regulate the host cyto-
skeleton and facilitate dissemination, and
how such information can translate
directly into a therapeutic strategy (Fig-
ure 2). Following replication in extranu-
clear factories, poxviruses utilize host
tyrosine kinases for release of virus parti-
cles from microtubules following trans-
port to the cell surface (Newsome et al.,
2004). After fusing with the plasma
membrane, poxviruses use Src- and
Abl-family tyrosine kinases in a redundant
fashion to propel the particles on actin-
filled membranous protrusions, called
‘‘tails,’’ toward apposing cells (Reeves
et al., 2005). Finally poxviruses utilize
Abl-family kinases to release from the in-
fected cell (Reeves et al., 2005). Remark-
ably, a large number of pathogens utilize
Abl- and related tyrosine kinases to regu-
late the host cytoskeleon or pathogen-
esis. These include pathogenic E. coli
(EPEC and EHEC [Swimm et al., 2004]),
Pseudomonas aeruginosa (Pielage et al.,specificity (Laub and Goulian, 2007; Paul
et al., 2008) (Figure 1C). Such structural
information has allowed ‘‘rewiring’’ of
signaling pathways. The same structural
information can be used to define small
molecules that have a similar effect.
Thus, it may be possible to develop drugs
that redirect signaling pathways control-
ling virulence (e.g., QseC) to perform
some other task, essentially subverting
regulation of the virulence program. While
attractive, such an approach may still
engender resistance in the pathogen,
especially if virulence per se reduces the
ability to compete with commensal
strains. However, such drugs may delay
expression of virulence allowing the
immune system time to react.
Designing Antimicrobial Drugs
that Target the Host
Establishment of infection requires avoid-
ance or subversion of host defenses,
together with movement within, on, or
between cells. When subverting host
systems, pathogens often utilize redun-
dant means, either by affecting multiple
factors within the same general pathway9 ª2009 Elsevier Inc.2008), Salmonella typhimurium (Ly and
Casanova, 2008), Shigella flexneri (Burton
et al., 2003), Helicobacter pylori (Tammer
et al., 2007), and Chlamydia trochomatis
(Elwell et al., 2008), among bacteria; and
orthopoxviruses (Reeves et al., 2005),
Coxsackie virus (Coyne and Bergelson,
2006), West Nile virus (Hirsch et al.,
2005), and Kaposi sarcoma virus (McAllis-
ter et al., 2005), among viruses.
Since the discovery that tyrosine
kinases become disregulated in cancer,
pharmaceutical chemists have been
developing inhibitors, some of which are
directed against the ATP binding site.
Although ATP binding sites of tyrosine
kinases are highly conserved, some selec-
tivity has been achieved. Nevertheless,
the capacity of tyrosine kinase inhibitors
to block multiple kinases within a family,
or multiple kinase families, makes them
potentially quite useful as antimicrobial
drugs, especially as many pathogens use
kinases in a redundant fashion. In this re-
gard, Gleevec (STI-571), which was devel-
oped as an anticancer drug to treat
chronic myelogenous leukemia resulting
from BCR-Abl translocations (Druker
et al., 2001; Goldman and Druker, 2001;
Traxler et al., 2001), inhibits both Abl and
the Abl-family kinase Abl2 (formerly called
Arg), and the structurally related kinase
c-kit (Heinrich et al., 2000). As noted
above, Abl-family kinases are used redun-
dantly by poxviruses for release. Conse-
quently, when administered prophylacti-
cally, Gleevec reduces mortality caused
by poxvirus infection (Reeves et al.,
2005). Whether Gleevec will work against
other pathogens that utilize Abl or related
kinases remains to be tested. Its efficacy
will depend on the particular set of kinases
used by the pathogen. In this regard,
kinase inhibitors with different, or even
looser, specificities may prove useful
against particular pathogens. Thus,
whereas Gleevec does not inhibit Tec-
family kinases, which together with Abl-
family kinases are required by EPEC to
form actin pedestals, PD-166326 inhibits
both kinase classes (Bommarius et al.,
2007; Swimm et al., 2004).
A primary concern when considering
drugs directed at host targets remains
their toxicity toward the host. Thus,
host molecules that are essential for
survival—or required to mount an effective
immune response—may prove difficult to
target. In this regard, some tyrosine
Cell Host & Microbe
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exhibited remarkably low toxicity, though
recent reports indicate effects on heart
(Kerkela et al., 2006; Mann, 2006) and on
the immune system (Agosti et al., 2004)
with long-term exposure. These concerns
may be mitigated, at least to some extent,
by adjusting dosing regimens and limiting
the period of exposure, conditions more
readily achievable for acute infections.
There may be other ways of mitigating
toxic effects. For several pathogens,
activity of host proteins required for path-
ogenesis (e.g., tyrosine kinases) is highly
upregulated during infection with various
pathogens. Thus, it may be possible to
develop inhibitors that, rather than
achieving complete inhibition, only block
the activated state without affecting basal
activity levels. Such a capacity is not
particularly sought after in cancer drugs,
but it may be useful for countering patho-
gens. Inhibitors directed at Src-family
kinases (e.g., PD-166326 and BMS-
354825 [Sprycel] [Shah et al., 2004]) may
prove particularly troublesome for path-
ogen infections because immune function
relies on Fyn. In this regard, toxicity of
these compounds is reportedly higher
than inhibitors such as Gleevec (Khakoo
et al., 2008; Porta et al., 2007; Pouessel
and Culine, 2008). One solution may be
to adjust the dosing regimens of more
potent inhibitors. Indeed, because the
requirement is simply to allow the immune
system time to develop an efficacious
response, short-term or punctuated
administration maybe all that is necessary.
Development of therapeutics directed
against host targets such as tyrosine
kinases may also provide a novel solution
to the problem of drug resistance.
Accordingly, such drugs would likely
engender less resistance compared to
traditional therapeutics because the
microbe would have to alter its entire
pathogenic strategy. In essence, the
drug might slow the spread and/or growth
of the microbe in the host, thereby giving
the host immune system time to mount
an effective response. This strategy has
been applied to parasites for decades
(e.g., the use of chloroquine for malaria),
and has been more recently been sug-
gested for bacteria and viruses (e.g.,
Reeves et al., 2005; Swimm et al., 2004).
Such drugs used in conjunction with tradi-
tional antimicrobial compounds would
extend the life span of the latter. More-over, because so many pathogens utilize
host signaling molecules that are dysre-
gulated in other diseases such as cancer,
it may be possible to repurpose drugs
already approved for use against those
targets and whose safety profiles are
well understood. In so doing, a plethora
of drugs may already be available to
combat the rise of multidrug-resistant
microbes. Indeed, it may be possible to
use drugs developed to combat one path-
ogen against other pathogens that use
similar sets of host proteins targeted by
that drug (‘‘pan-inhibitors’’).
Recent work using RNAi or siRNA
libraries directed against the human
genome have identified large numbers of
molecules as putative host factors in path-
ogenesis and represent a treasure trove of
potential therapeutic targets (Brass et al.,
2008; Elwell et al., 2008; Pielage et al.,
2008). However, these data must be
viewed cautiously because RNAi can
inhibit, directly or indirectly, other family
members or even other redundant mole-
cules. In addition, because screens are
typically carried out on cultured cells with
viruses or bacteria selected for use
in vitro, identified targets may not neces-
sarily prove important in vivo. Moreover,
a pathogen may use additional redundant
means not recapitulated in tissue culture
systems. In short, all hits will require vali-
dation both in vitro and in vivo. Another
promising means to find safe therapeutic
targets is to use genetic screens in mice,
which can identify host factors required
for pathogenesis that are not lethal when
mutated (Beutler and Moresco, 2008).
Targeting the Host-Pathogen
Interface
Insights into how virulence factors inter-
face with host factors is crucial to devel-
opment of host-targeted therapeutics, in
part because specifically targeting the
interaction of virulence factors with host
molecules may be a means to reduce
toxicity. For example, mutational and
modeling studies suggest that the EPEC
virulence factor Tir has evolved proline-
rich regions and phosphotyrosine resi-
dues that facilitate stable and direct
binding to SH3 and SH2 domains of target
cellular kinases (Bommarius et al., 2007),
thereby mimicking cellular ligands that
normally activate these kinases (Dueber
et al., 2004). When docked, the proline-
rich region fits much more loosely intoCell Host & Microbe 5,the kinase SH3 domain than cellular
ligands. Nevertheless, the interaction
remains somewhat specific because
Src-family kinases are excluded from in-
teracting with Tir based on sequence
motifs within the proline-rich region and
surrounding the phosphotyrosine. These
observations raise the possibility of
designing inhibitors that disrupt the inter-
actions of kinase with virulence factors,
but not with normal cellular targets.
Successful design of such ‘‘interface’’
inhibitors is not without problems. Crystal
structures reveal the complexity of the
interaction, which creates formidable
difficulties in drug design. As an illustra-
tion, consider retrovirus budding, which
requires small protein motifs (late
domains) within the viral Gag protein that
recruit cellular factors such as ALIX, and
members of the endosomal sortin
complex required for transport (ESCRT)-I
and -III complexes (e.g., Tsg101) to
promote membrane fission (Fisher et al.,
2007; Hurley and Emr, 2006; von Schwe-
dler et al., 2003). Recent evidence indi-
cates that proteins mediating retroviral
budding also regulate cytokinesis (Carlton
and Martin-Serrano, 2007; Morita et al.,
2007). Structural analysis of ALIX in
complex with the YPXnL late domain
motifs of HIV-1 Gag and EIAV peptide re-
vealed that different late domains bind at
the same site on the ALIX but adopt
different conformations. Because the viral
YPXnL peptides bind to conserved resi-
dues on the ALIX surface, it may be that
such late domains have evolved to mimic
interactions of cellular ALIX binding part-
ners. Indeed, the late domains of Gag
proteins of many viruses, or even other
motifs in related viruses (e.g., SIV, which
lack the YPXnL motif), may collectively
mimic the space of normal activators of
multifunctional proteins such as ALIX, to
facilitate budding (Carlton and Martin-
Serrano, 2007). Detailed structural infor-
mation is crucial to the design of inhibitors
that can distinguish host proteins from
virulence factors yet cover the ‘‘space’’
of known interactors, as well as those
which can arise under selective pressure
(e.g., Zamborlini et al., 2006). Such struc-
tural information can also permit design of
inhibitors that maintain binding sites for
negative regulators of host factors, or
function as allosteric inhibitors, or inhibi-
tors that stabilize molecules in ‘‘downre-
gulated’’ states (e.g., Chan et al., 1997;February 19, 2009 ª2009 Elsevier Inc. 117
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alternative to the design approach is to
use FRET-based high-throughput screen-
ing techniques based on protein-protein
interactions, which in principle can sam-
ple a larger space of inhibitor geometries.
Complexity in the Host Innate
Immune System
The necessity of pathogen detection by
hosts has lead to the evolution of multiple,
potentially redundant sets of innate
immune receptors that recognize patho-
gens, called pattern recognition receptors
(PRRs). For example, the signaling path-
ways from at least two PRR families,
Toll-like receptors (TLRs) and NOD-like
receptors (NLRs), orchestrate both
protection against invading pathogens
and homeostasis with commensal organ-
isms (Kufer and Sansonetti, 2007). These
highly conserved receptors provide the
host a means to respond to ‘‘nonself’’
following recognition of microbe-associ-
ated molecular patterns (MAMPs). PRRs
are capable of detecting multiple different
structural motifs that are potentially pre-
sented by the same pathogen, including
proteins (e.g., flagellin detected by
TLR5), lipids (e.g., lipid A of LPS detected
by TLR4), sugar complexes (e.g., peptido-
glycan detected by NOD1 and NOD2),
and nucleic acids (e.g., CpG DNA de-
tected by TLR9) (Kaisho and Akira, 2004;
Philpott and Girardin, 2004). Following
receptor engagement with their ligands,
signaling cascades are initiated that acti-
vate transcription factors such as NF-kB
(Kaisho and Akira, 2004; Philpott and Gir-
ardin, 2004). Different TLRs and NLRs
utilize slightly different combinations of
signaling intermediates (Kaisho and Akira,
2004; Kufer and Sansonetti, 2007), and
recent evidence indicates significant
crosstalk between molecules acting distal
to TLRs and NLRs. For example, adminis-
tration of the peptidoglycan subunit mur-
amyl dipeptide (recognized by NOD2)
renders mice more sensitive to TLR
ligands, including LPS, lipopeptides, and
CpG DNA, by inducing expression of
signaling intermediaries such as MyD88
(Takada et al., 2002). Thus, in response
to an intact pathogen, several receptors
appear to activate convergent and diver-
gent signaling pathways within the same
host cell, allowing both flexibility and
specificity in coordinating the innate
immune response.118 Cell Host & Microbe 5, February 19, 2009In such a combinatorial system, many
PRRs may contribute to the innate immune
response to a particular pathogen and
determine whether the overall outcome is
protective or deleterious to the host.
Indeed, some pathogens, such as the
mouse A/E pathogen Citrobacter roden-
tium, may hyperactivate TLR signaling
and induce superfluous levels of inflamma-
tion that exacerbates the infection and it-
self constitutes disease (Luperchio and
Schauer, 2001). By contrast, a protective
role for TLR or NLR signaling has also
been demonstrated, indicating that simply
inhibiting various PRR signaling cascades
may be dangerous. For example,
myeloid-differentiation factor-88 (MyD88)
mediates NF-kB activation by most TLRs
(Kaisho and Akira, 2004), and studies
with MyD88/ mice demonstrate
a protective role for this adaptor in infec-
tions caused by viruses (Zhou et al.,
2005), parasites (Bolz et al., 2004), bacte-
rial pathogens (e.g., Lebeis et al., 2007;
Weiss et al., 2005), and even commensal
bacteria present in the intestine (Fukata
et al., 2005; Rakoff-Nahoum et al., 2004).
Furthermore, there exists a positive corre-
lation between mutations in NOD2 and
chronic inflammatory conditions, such as
Crohn’s disease (Hugot et al., 2001). Inter-
estingly, mutations in NOD2 that are asso-
ciated with Crohn’s disease are often
found in the ligand-binding domain. As
a result, these mutations eliminate the
specificity by which NOD2 activates NF-
kB and inflammatory cytokine production,
thereby causing indiscriminate intestinal
inflammation (Hugot et al., 2001). Thus,
the balance between protective antimicro-
bial responses and destructive inflamma-
tory responses is determined by the path-
ogen in conjunction with a complex the
innate immune signaling network that it
stimulates in the host.
Emerging Anti-inflammatory
Therapeutics
Data such as in the examples outlined
above have important ramifications for
drug design. Therapeutics directed
against innate immune signaling compo-
nents must be ‘‘tuned’’ to preserve protec-
tive immune responses while maintaining
the ability to counter deleterious ones.
Despite the complexity, it is possible to
develop therapeutic compounds that
satisfy these criteria. Hancock and
colleagues have proposed the use ofª2009 Elsevier Inc.immunomodulatory antimicrobial or
host-defense peptides (AMPs or HDPs)
that are capable of facilitating the antimi-
crobial immune response, while mollifying
disease and tissue destruction associated
with inflammation (Hancock and Sahl,
2006; Scott et al., 2007) (Figure 3). AMPs
have evolved within both mammals and
microbes (Woolhouse et al., 2002). Cycles
of selection during evolution have resulted
in a diverse repertoire of peptides, which
kill bacteria and viruses by multiple means
(e.g., Sahl et al., 2005). Bacteria have adap-
ted by developing resistance, by inactivat-
ing AMPs (e.g., Staphlococcus aureus sta-
phlokinase [Jin et al., 2004]), by extrusion of
AMPs (e.g., Neisseria gonorrhoea MtrCDE
[Shafer et al., 1998], or by other means
(e.g., Ernst et al., 2001; Peschel, 2002).
Such parries have been countered by
further expansion of the repertoire. Of
particular interest here is that mammals
have coordinately developed peptides
with immunomodulatory activity, some of
which also have antimicrobial activity,
such as LL-37 (Marr et al., 2006). Hancock
and colleagues have now engineered
‘‘tuned’’ peptides, each with particular
immunomodulatory capabilities (Hancock
and Sahl, 2006; Scott et al., 2007). One
such peptide, IDR-1, is effective against
a variety of infections in vivo including
MRSA and S. typhimurium (Scott et al.,
2007). More remarkable still, although
suchpeptideshavea shorthalf-life inserum
(1 hr), they appear toproduce long-lasting
changes in the immune response, likely by
affecting intracellular targets (R. Hancock,
personal communication). Injection of
IDR-1 peptide the day prior to infection
with a dose of S. aureus that would other-
wise prove lethal, can provide significant
protection (Scott et al., 2007). This tech-
nology has the capacity to be of enormous
benefit in a variety of scenarios, including
infections with attendant inflammation,
infections caused drug-resistant microbes,
and even vaccines (Marr et al., 2006).
However, AMPs or HDPs may not be
appropriate for all infections. Targeting
innate immune functions may facilitate
pathogen spread, HDPs that target the
innate immune systems appropriate for
a particular pathogen may not yet exist,
and efficacy may depend on when the
peptides are administered (e.g., prophylac-
tically or therapeutically).
A second strategy for combating inflam-
matory disease derives from pathogens
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(Right) Activation of the host innate immune response by bacterial PAMPs results in activation of TLR- and MAP kinase signaling, which in turn causes upregu-
lation of proinflammatory cytokines, such as TNF-a, chemokines, as well an anti-inflammatory chemokines that mollify the proinflammatory response. Recruit-
ment of effectors to the site of the infection clears the pathogen, but may cause potentially harmful side effects such as tissue damage.
(Left) In the presence of HDPs such as IDR-1, TLR-NF-kB signaling is modified and anti-inflammatory signaling increased; as a result, effector mechanisms are
altered so as to control the infection without exacerbating inflammation. Adapted from Scott et al. (2007) and used with permission of R. Hancock and Nature
Biotechnology.Cell Host & Microbe 5dant pathways, which together must be
disrupted to block infection. The develop-
ment of such networks serves a number
of practical purposes including develop-
ment of biomarkers for clinical diagnosis,
and for defining drug targets. Further-
more, biomarkers can also be used to
assess, for example, toxicity, immune
regulation, or other parameters associ-
ated with positive clinical outcomes for
drugs or vaccines (e.g., Furnari et al.,
2007; Stommel et al., 2007).
Systems-based approaches have been
applied extensively in cancer biology to
define signaling ‘‘networks’’ (e.g., the
tyrosine phosphoproteome) that govern
growth of transformed breast cancer cell
lines in vitro and tumors in vivo (Kim and
White, 2006; Zhang et al., 2005). Such
approaches are, in the best cases, driven
by complex quantitative data sets and
able to generate testable predictions.
Techniques such as iTraq, for example,
allow highly sensitive and quantitative
assessment of the levels of phosphoryla-
tion of peptides between samples, and
identification of phosphorylation sitesmass sequencing approaches, and
highly sensitive mass spectroscopy (MS)
approaches, have important ramifications
for understanding signaling complexity
that underlies host-pathogen interac-
tions, as well as drug and vaccine design.
Here we focus on the potential utility of
MS approaches in defining the putative
‘‘infectome,’’ and suggest ways that
such information may be applicable to
the design of more efficacious drugs or
vaccines for many pathogens. The ‘‘in-
fectome’’ might include, for example,
a collection of experimentally defined
signatures or markers (e.g., phosphoryla-
tion or methylation sites) within proteins of
both the pathogen and the host that are
critical for infection. Indeed, signaling
elements within the ‘‘infectome’’ may, de-
pending on the infection, overlap those
elements regulating inflammation. Impor-
tantly, the experimental design of such
systems-based MS approaches can
accommodate complexity and redun-
dancy issues by identifying a network of
signaling molecules or markers that
encompass several functionally redun-themselves a variety of which have
evolved defense mechanisms to interfere
with or mollify host innate and acquired
immune responses. One example is
Serp-1 from Myxoma viruses, which has
potent anti-inflammatory activity and tar-
gets the plasminogen activators and
plasmin (Dai et al., 2006; Turner and
Moyer, 2002). Serp-1 protein in animal
models after vascular surgery reduces
inflammation and formation of atheros-
chlerotic plaques (Bedard et al., 2006;
Jiang et al., 2007). The anti-inflammatory
activity of Serp-1 is currently being
explored in the context of a variety of
inflammatory disease models (Richardson
et al., 2006). It is possible that Serp-1 or
molecules with similar activity will likewise
have utility in infectious models, where
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Perspectivewithin proteins by MS/MS (Ross et al.,
2004). No experimental technique, in-
cluding iTraq, will define the phosphopro-
teome (or any other ‘‘-ome’’) in its entirety.
The goal is to generate a data set of suffi-
cient complexity such that targets identi-
fied by proteomics approaches can be
defined and then validated in a biological
system.
The question arises as to how one prior-
itizes which targets to characterize
further. A relatively unbiased approach is
to take advantage of computational
methods that assess that phosphopro-
teins contribute most to the variance
between several independently acquired
data sets (e.g., infection of cell lines lack-
ing particular kinases or inhibitors that
block particular subsets of kinases).
Importantly, complexity of the data sets,
particularly with respect to representation
of low abundance peptides, is critical to
this analysis, because even low abun-
dance peptides can be accurate predic-
tors of signaling. Using these data, bioin-
formatics and computational modeling
techniques (e.g., hierarchical clustering
and self-organizing maps) have identified
phosphorylation sites that best fit the
experimental protocols. These tech-
niques have been used to define all
peptides whose phosphorylation corre-
late cellular transformation during breast
cancer (Kim and White, 2006; Kumar
et al., 2007). Additional computational
methods (e.g., principal component anal-
ysis) are required to generate a network of
peptides within the correlation cluster that
best predict the biological response to
a given stimulus (Kumar et al., 2007).
While it is tempting to speculate that
a particular tyrosine site within a protein
or a particular protein may be most impor-
tant, data with breast cancer cells
suggests that this is not the case. A
network of some 100 phosphopeptides
within 70 proteins has been identified in
data sets, some of which are at low abun-
dance, that as a group account for the
behavior of the system under the different
experimental conditions (Kumar et al.,
2007). The peptides identified are in ef-
fect functionally redundant. Testing the
predictions of the network model requires
validation by mutating each of these sites
alone or in groups in the context of a cell
culture or animal model.
Signaling networks can also serve as
the basis for developing biomarkers for120 Cell Host & Microbe 5, February 19, 2009diagnostic purposes, or for assessing
the efficacy of drugs. In this regard, tar-
geted therapies that inhibit particular
receptor tyrosine kinases and down-
stream signaling pathways have shown
promise in some cancers but not others.
By profiling tyrosine kinase activity and
signaling networks in these nonrespon-
sive tumors, DiPinho and colleagues
have shown that combinations of tyrosine
kinase inhibitors and RNA interference,
but not particular therapies alone, were
efficacious in reducing parameters asso-
ciated with progression of complex,
genetically unstable tumors such as glio-
blastoma multiforme (Furnari et al., 2007;
Stommel et al., 2007). Such methodolo-
gies may also be useful in profiling effects
of drugs on signaling molecules associ-
ated with infectious diseases, or with
vaccines.
Conclusions
We have presented here examples of how
an understanding of the host-pathogen
interface can facilitate development of
therapeutic strategies. Thus, targeting
two-component regulatory systems in
bacteria to ‘‘rewire’’ regulators of viru-
lence, or targeting host molecules that
mediate pathogen dissemination, can
treat infections while reducing the possi-
bility of developing resistance. For the
immune system, use of antimicrobial
peptides or viral proteins that limit inflam-
mation yet preserve the antimicrobial
capacity of the immune system offer
promise against pathogens in which the
inflammation constitutes the disease.
For pathogens that thwart the host
immune response by adapting around it,
strategies that alter pathogenesis so as
to induce a broader adaptive response
may be applicable. Finally, tools from
cancer and systems biology may prove
useful both in defining the complex
signaling networks during infection and
in evaluating the efficacy of drugs and
vaccines. Together, these approaches
offer ways to understand the complexities
of host-microbe interactions, and to facil-
itate drug and vaccine design.
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